Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 12 Week, Phase 3, Double-blind, Randomized, Placebo-controlled, Parallel Group Study To Assess The Efficacy, Safety, Tolerability And Actual Use Of Bococizumab And An Autoinjector (Pre-filled Pen) In Subjects With Primary Hyperlipidemia Or Mixed Dyslipidemia

NCT02458287 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT02458287
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02458287 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 12 Week, Phase 3, Double-blind, Randomized, Placebo-controlled, Parallel Group Study To Assess The Efficacy, Safety, Tolerability And Actual Use Of Bococizumab And An Autoinjector (Pre-filled Pen) In Subjects With Primary Hyperlipidemia Or Mixed Dyslipidemia
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Completed
Start date
June 30, 2015
Completion date
February 29, 2016
Enrollment
299 (actual)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

hyperlipidemia